TheraRadar

Chipscreen

Pre-Approval PRO BETA
37
Total Trials
10
Phase 3
13
Phase 2
9
Recruiting
336
Score

Pipeline by Phase

Phase 3
10
Phase 2
13
Phase 1
19

Therapeutic Focus

Small Cell Lung Cancer Ovarian Cancer Type 2 Diabetes Healthy Non Small Cell Lung Cancer

Clinical Trials (37)

NCT06497985 Phase 3 RECRUITING

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Started: 12/6/2024

NCT06947967 Phase 3 RECRUITING

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Started: 8/12/2025

NCT04921527 Phase 3 RECRUITING

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Started: 12/20/2021

NCT04231448 Phase 3 COMPLETED

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Started: 5/21/2020

NCT07445295 Phase 3 NOT YET RECRUITING

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Started: 3/31/2026

NCT04830813 Phase 3 COMPLETED

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Started: 3/5/2021

NCT04807348 Phase 3 COMPLETED

Chiglitazar Added to Metformin for Type 2 Diabetes

Started: 7/6/2021

NCT02482753 Phase 3 COMPLETED

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Started: 7/1/2015

NCT02173457 Phase 3 COMPLETED

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Started: 9/1/2014

NCT02121717 Phase 3 COMPLETED

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

Started: 6/1/2014

NCT06492915 Phase 2 ACTIVE NOT RECRUITING

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Started: 8/13/2024

NCT05497843 Phase 2 COMPLETED

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Started: 8/25/2022

NCT05336721 Phase 2 TERMINATED

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Started: 11/5/2021

NCT05068427 Phase 2 COMPLETED

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Started: 11/23/2021

NCT05519865 Phase 2 COMPLETED

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Started: 10/26/2022

NCT05193916 Phase 2 COMPLETED

A Phase II Clinical Trial of Chiglitazar for NASH

Started: 3/21/2022

NCT03901118 Phase 2 COMPLETED

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Started: 7/1/2019

NCT01836679 Phase 2 COMPLETED

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Started: 4/1/2013

NCT06245122 Phase 1 RECRUITING

A Study of CS23546 in Subjects With Advanced Tumors

Started: 3/27/2024

NCT07129382 Phase 1 RECRUITING

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

Started: 9/8/2025

NCT06902350 Phase 1 RECRUITING

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

Started: 5/21/2025

NCT05271292 Phase 1 RECRUITING

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Started: 8/26/2022

NCT05979155 Phase 1 RECRUITING

A Study of NWY001 in Subjects With Advanced Solid Tumors

Started: 1/5/2024

NCT07511010 Phase 1 NOT YET RECRUITING

Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

Started: 10/8/2026

NCT06224595 Phase 1 COMPLETED

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules

Started: 3/28/2024

NCT05515458 Phase 1 COMPLETED

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Started: 11/20/2022

NCT05515445 Phase 1 COMPLETED

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Started: 12/3/2022

NCT05922709 Phase 1 COMPLETED

A Clinical Trial of CS12192 in Healthy Subjects

Started: 7/20/2023

NCT03216343 Phase 1 COMPLETED

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Started: 11/9/2017

NCT05681273 Phase 1 COMPLETED

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Started: 2/17/2023

NCT05346601 Phase 1 COMPLETED

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

Started: 6/2/2022

NCT03974243 Phase 1 COMPLETED

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Started: 7/11/2019

NCT03245190 Phase 1 COMPLETED

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Started: 4/28/2018

NCT03166891 Phase 1 COMPLETED

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Started: 12/15/2017

NCT03074825 Phase 1 TERMINATED

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Started: 5/9/2017

NCT02809573 Phase 1 COMPLETED

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Started: 8/11/2016

NCT02122809 Phase 1 COMPLETED

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Started: 2/1/2014

Drug Candidates

R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) Tucidinostat Placebo Chiglitazar/Metformin extended-release tablets under fasting conditions Chiglitazar/Metformin extended-release tablets after a high-fat meal multiple-dose of Chiglitazar/Metformin extended-release tablets CS23546 Sintilimab Bevacizumab Fruquintinib
Activity Status: Active
Last Trial Started: 10/8/2026
Last Trial Ended: 6/29/2025
Trials (12 months): 5
Completed Trials: 24
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.